People: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

29.91USD
16 Sep 2014
Price Change (% chg)

$0.24 (+0.81%)
Prev Close
$29.67
Open
$29.66
Day's High
$30.00
Day's Low
$29.47
Volume
253,855
Avg. Vol
515,498
52-wk High
$39.94
52-wk Low
$27.51

Search Stocks

Hindman, Andrew Asa 

Brief Biography

Mr. Andrew Hindman is Chief Business Development Officer of the Company. Mr. Hindman has held several senior executive level positions in the biopharmaceutical industry, most recently as President, Chief Executive Officer and member of the Board of Tobira Therapeutics, a privately-held biotechnology company. At Tobira, he was responsible for developing a new corporate strategy, building new leadership and operational teams, and raising operating capital. Prior to Tobira, Mr. Hindman held senior corporate development and commercial operating positions at Nodality, Onyx Pharmaceuticals and Gilead Sciences. Mr. Hindman holds a B.A. in biochemistry and economics, graduating Phi Beta Kappa from Wesleyan University, and an executive MBA from Columbia University and the University of California Berkeley, Haas School of Business.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ron Cohen

3,918,020

Michael Rogers

4,352,770

Lauren Sabella

1,060,110

Andrew Blight

1,484,560

Jane Wasman

2,159,620

Enrique Carrazana

1,618,840
As Of 30 Dec 2013
Search Stocks